Celldex Therapeutics Inc
CLDXHealthcare|Biotechnology|USA
$39.11
+0.14 (+0.36%)
Tangible Book
$6.45
Upcoming Data Readouts (10)
Oct 2026
Est. completion
P3Chronic Spontaneous Urticaria
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023n=963
Oct 2026
Est. completion
P3Chronic Spontaneous Urticaria
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202n=976
Dec 2026
Est. completion
Mar 2027
Est. completion
P1Mild to Moderate Asthma
A Study of CDX-622 in Participants With Mild to Moderate Asthma
NCT07330778n=12
Mar 2027
Est. completion
P2Ovarian Clear Cell Adenocarcinoma
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT05231122n=80
Mar 2027
Est. completion
P2Glioblastoma
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
NCT03688178n=43
Apr 2027
Est. completion
P1Malignant Epithelial Neoplasms
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
NCT05349890n=1
Dec 2027
Est. completion
Apr 2028
Est. completion
P1HER2-negative Breast Cancer
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
NCT05029999n=30
Jun 2028
Est. completion
P3Chronic Inducible Urticaria
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT07266402n=240
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.